Key result
Checkpoint inhibitor cardiotoxicity represents a major clinical challenge requiring careful surveillance and management.
Key points are not available for this paper at this time.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Brüstle et al. (2017) studied this question. Checkpoint inhibitor-induced cardiotoxicity is a significant drawback of novel anticancer agents that requires careful clinical management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: